SCHEDULE: Vestal Point Capital Discloses 9.9% Stake in iBio

Vestal Point Capital, LP and Ryan Wilder have reported a 9.9% beneficial ownership stake in iBio, Inc., primarily through warrants.

Summary

• Vestal Point Capital, LP and Ryan Wilder have filed a Schedule 13G, disclosing beneficial ownership of 9.9% of iBio, Inc.'s Common Stock.
• The ownership consists of 4,275,000 shares of Common Stock issuable upon the exercise of warrants.
• These warrants are subject to a 9.99% blocker, preventing exercise if it would result in ownership exceeding 9.99% of iBio's outstanding Common Stock.
• The reported 9.9% ownership percentage reflects the application of this 9.99% blocker.
• The calculation is based on 19,654,636 shares of iBio Common Stock outstanding as of September 4, 2025, as reported in the company's Annual Report on Form 10-K.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of iBio, except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership, which is neutral in tone. The acquisition of a significant stake by an institutional investor could be seen as mildly positive, but the filing itself is purely informational.

Positives

• A significant institutional investor, Vestal Point Capital, has taken a substantial stake in iBio, potentially signaling confidence in the company's long-term prospects.

Risks

• The warrants are subject to a 9.99% blocker, which limits the immediate exercisability of the full 4,275,000 shares and could impact the reporting persons' ability to increase their stake beyond this threshold without further disclosures or actions.

Future Outlook

NA

Management Comments

• The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
• I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake could be viewed positively, potentially increasing investor confidence or signaling future interest. The 9.99% blocker limits immediate dilution from warrant exercise.

Next Steps

• Vestal Point Capital, LP and Ryan Wilder will be responsible for timely filing of subsequent amendments to this Schedule 13G.

Key Dates

Recommendation

This filing indicates a significant institutional stake, which can be a positive signal. However, it's a factual ownership report and does not provide new operational or financial performance data for iBio. Investors should hold and await further operational updates or financial results from iBio to make a more informed decision. The 9.99% blocker on warrant exercise is a notable detail.

Keywords

iBio Inc, Vestal Point Capital, Ryan Wilder, Schedule 13G, beneficial ownership, common stock, warrants, equity stake, investment adviser